HOPKINTON, Mass., Nov. 19 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. , a leading provider of tools and services for drug discovery and life sciences research, today announced a strategic partnership between the company’s contract research organization, Caliper Discovery Alliances & Services (CDAS), and Prestwick Chemical (Strasbourg, France) to provide customized outsourced medicinal chemistry and in vitro and in vivo preclinical biology programs for drug discovery research. The non-exclusive co-marketing agreement offers complete chemistry and biology research programs to help pharmaceutical and biotechnology customers increase identification of lead compounds.
“Outsourcing complete chemistry-biology research programs answers an industry need for increased productivity, efficiency and turnaround time in the drug development process,” said David Manyak, executive vice president, drug discovery services, Caliper Life Sciences. “By providing integrated chemistry and biology programs, researchers now have a unique opportunity to access combined best in class chemistry and preclinical biology research that is invaluable in identifying safe and effective new drug candidates while minimizing commitment of internal resources.”
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com
Caliper is a registered trademark of Caliper Life Sciences, Inc.
Caliper Life Sciences, Inc.
